替吉奥胶囊联合康莱特注射液治疗晚期胰腺癌的疗效观察

Efficacy of tegafur gimeracil oteracil potassium capsule combined with kanglaite injection for advanced pancreatic carcinoma

目的了解替吉奥胶囊联合康莱特注射液治疗晚期胰腺癌患者的近期疗效、毒副反应及对生活质量的改善程度。方法 53例晚期胰腺癌患者随机分为两组,试验组(n=27)给予替吉奥胶囊联合康莱特注射液治疗,对照组(n=26)单独给予替吉奥胶囊口服,2个周期后进行疗效评定。结果试验组近期有效率和疾病控制率分别为33.3%、70.4%,对照组分别为19.2%、46.2%,两组比较差异均无统计学意义(P>0.05)。两组胃肠道反应、神经毒性、肝肾毒性等相似,均为Ⅰ、Ⅱ度。试验组KPS评分改善率为74.1%,体重增加率为59.3%,疼痛改善率为63.0%,均优于对照组的34.6%、26.9%、26.9%,差异有统计学意义(P<0.05)。结论替吉奥胶囊联合康莱特注射液治疗晚期胰腺癌患者可以改善生活质量,为姑息治疗的选择之一。

Objective To analyze the efficacy, adverse effects and quality of life in advanced pancreatic carcinoma treated with tegafur gimeracil oteracil potassium capsule combined with kanglaite injection. Methods A total of 53 patients with pancreatic carcinoma were randomly divided into the trial group（27 patients） and the control group（26 patients）. The trial group received tegafur gimeracil oteracil potassium capsule combined with kanglaite injection; the control group received only tegafur gimeracil oteracil potassium capsule. After two cycles, the efficacy, adverse dffects and quality of life were evaluated. Results The resent curative effect and disease control rate of the trial group were 33.3%and 70.4%, respectively; the control group were 19.2% and 46.2% respectively; the differences of the two group had no statistical significance（P〉0.05）. The gastrointestinal reaction, neurotoxicity, hepatotoxiciy, nephrotoxicity myelosuppression of the two groups were roughly similar, both were grade Ⅰ, Ⅱ. But the improved of Karnofsky performance status scale rate, increased weight rate, decreased pain rate of trial group（74.1%, 59.3%, 63.0%） was better than control group（34.6%, 26.9%, 26.9%）（P〈0.05）. Conclusion The treatment of tegafur gimeracil oteracil potassium capsule combined with kangliate injection could improve the quality of life, it＇s a better choice for advanced pancreatic carcinoma.